Traws Pharma, Inc. (TRAW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1M 2M 3M Q1 '21: 235K Q2 '21: 236K Q3 '21: 227K Q4 '21: 226K Q1 '22: 226K Q2 '22: 226K Q3 '22: 226K Q4 '22: 226K Q1 '23: 226K Q2 '23: 226K Q3 '23: 226K Q4 '23: 226K Q1 '24: 226K Q2 '24: 226K Q3 '24: 226K Q4 '24: 226K Q1 '25: 227K Q2 '25: 2.9M Q3 '25: 2.8M Q4 '25: 2.8M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -19M Q4 '21: -16.5M Q1 '22: -16.5M Q2 '22: -16M Q3 '22: -17.7M Q4 '22: -19.6M Q1 '23: -21.6M Q2 '23: -22.1M Q3 '23: -21.6M Q4 '23: -20.3M Q1 '24: -19.4M Q2 '24: -138.1M Q3 '24: -141.6M Q4 '24: -142.4M Q1 '25: -142.4M Q2 '25: -20.3M Q3 '25: -15.8M Q4 '25: -17.9M Q1 '26: -19.6M Q2 '26: -21.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -18.8M Q4 '21: -16.2M Q1 '22: -15.6M Q2 '22: -15.4M Q3 '22: -17.3M Q4 '22: -19M Q1 '23: -20.6M Q2 '23: -20.8M Q3 '23: -20.2M Q4 '23: -18.9M Q1 '24: -18.2M Q2 '24: -137M Q3 '24: -140.8M Q4 '24: -166.5M Q1 '25: -140.1M Q2 '25: -17.8M Q3 '25: -13.3M Q4 '25: 9.2M Q1 '26: -19.4M Q2 '26: -21.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -20.7M Q4 '21: -19.5M Q1 '22: -17.1M Q2 '22: -17M Q3 '22: -16.7M Q4 '22: -16.3M Q1 '23: -16.5M Q2 '23: -16.8M Q3 '23: -17.4M Q4 '23: -17.9M Q1 '24: -17.8M Q2 '24: -23.2M Q3 '24: -30.2M Q4 '24: -29.8M Q1 '25: -30.8M Q2 '25: -26.9M Q3 '25: -19.5M Q4 '25: -18.2M Q1 '26: -15.3M Q2 '26: -16.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '13: -62M Q1 '14: -64M Q2 '14: -62M Q3 '14: -60.8M Q4 '14: -57.9M Q4 '13 Q1 '14 Q2 '14 Q3 '14 Q4 '14

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q1 '21: 14.6M Q2 '21: 15.8M Q3 '21: 16M Q1 '22: 20.9M Q2 '22: 20.9M Q3 '22: 20.9M Q1 '23: 21M Q2 '23: 21M Q3 '23: 840.1K Q1 '24: 841.7K Q2 '24: 1M Q3 '24: 961.5K Q1 '25: 7.2M Q2 '25: 5.8M Q3 '25: 8.8M Q1 '26: 10.6M Q2 '26: 15.9M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q2 '20: -0.28 Q3 '20: -0.05 Q4 '20: -2.17 Q1 '21: -2.46 Q2 '21: -2.08 Q3 '21: -1.78 Q4 '21: -0.97 Q1 '22: -0.85 Q2 '22: -0.77 Q3 '22: -0.81 Q4 '22: -0.91 Q1 '23: -0.99 Q2 '23: -1.00 Q3 '23: -6.38 Q4 '23: -11.10 Q1 '24: -16.74 Q3 '25: -5.64 Q4 '25: 0.82 Q1 '26: -1.80 Q2 '26: -1.85 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.